Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
Recruiting · NCT07010302 · Registry updated 2026-09-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD | NMOSD | Recruiting | Phase 4 | 2026-09-24 | NCT07010302 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Charite University, Berlin, Germany | 188 |
| Massachusetts General Hospital | 758 |
| Patient-Centered Outcomes Research Institute | 213 |
| The Sumaira Foundation | 1 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Charité - Universitätsmedizin Berlin | Berlin | Germany | 21 |
| Massachusetts General Hospital | Boston | United States | 1015 |